Down Syndrome Screening in Hong Kong IVF: PGT-A Technology and Applicable Conditions Explained

AI Summary

A. Direct Answer to the Question: Yes, but with Strict Boundaries

Hong Kong IVF clinics can indeed perform preimplantation genetic testing (PGT-A, aneuploidy screening) for Down syndrome. This technology analyzes the chromosome number of embryos to select chromosomally normal embryos for transfer.

• Key Fact: Down syndrome (Trisomy 21) is one of the standard detection targets of PGT-A.
• Scope of Testing: PGT-A detects numerical chromosomal abnormalities, not all genetic diseases.
• Accuracy: The screening accuracy is approximately 95–99%, but there are technical limitations.

B. Why Can PGT-A Screen for Down Syndrome?

The root cause of Down syndrome is an extra copy of chromosome 21 (trisomy 21). PGT-A technology involves removing approximately 5–10 trophectoderm cells from a blastocyst developed to day 5–6 and analyzing the chromosomal composition of these cells using high-throughput sequencing (NGS) or microarray technology to determine if the embryo has trisomy 21.

Technical Principle Summary Table

C. Doctor's Perspective: Indications and Limitations

Indications

• Maternal age ≥ 35 years (especially ≥ 38 years)
• Previous history of aneuploid pregnancy (e.g., trisomy 21, trisomy 18)
• One partner is a carrier of a chromosomal structural abnormality (e.g., balanced translocation)
• History of recurrent miscarriage (≥ 2 times)
• Severe male factor infertility (may increase the rate of embryonic chromosomal abnormalities)

Limitations (Must be clearly communicated by the doctor)

• Mosaicism Issue: Embryos may contain a mix of normal and abnormal cells (mosaicism). The biopsied cells may not fully represent the entire embryo, leading to missed detection or misdiagnosis.
• Scope of Testing: PGT-A only detects numerical chromosomal abnormalities and some structural abnormalities. It cannot detect single-gene disorders (e.g., thalassemia, cystic fibrosis) or microdeletions/duplications.
• Impact on Embryo: The potential impact of the biopsy itself on the embryo is still under research. It is currently considered relatively safe for blastocyst biopsy, but not zero-risk.
• No Embryo for Transfer: For women of advanced age, all embryos may be chromosomally abnormal, resulting in no embryos available for transfer.

G. The Most Easily Overlooked Detail: PGT-A Cannot Replace Prenatal Diagnosis

This is the most easily overlooked point. Even after transferring a chromosomally normal embryo via PGT-A, prenatal diagnosis (amniocentesis or chorionic villus sampling) is still required after pregnancy. Reasons are as follows:

• PGT-A tests trophectoderm cells (which will develop into the placenta), not the fetus itself. In rare cases, there can be discordance between placental and fetal chromosomes (confined placental mosaicism).
• PGT-A technology itself has a certain false negative rate (approximately 1–5%), meaning an embryo is actually abnormal but tested as normal.

H. Common Pitfalls

I. Actual Process: Hong Kong IVF + PGT-A

1. Initial Assessment: Female AMH, FSH, antral follicle count; male semen analysis; chromosomal karyotyping for both partners, genetic counseling.
2. Ovarian Stimulation: Approximately 10–14 days, monitoring follicle development.
3. Egg Retrieval: Ultrasound-guided egg retrieval.
4. Fertilization: Conventional IVF or ICSI (ICSI is recommended to avoid sperm DNA contamination).
5. Blastocyst Culture: Culture to day 5–6.
6. Embryo Biopsy: Remove 5–10 cells from the trophectoderm of the blastocyst.
7. Embryo Freezing: Embryos are frozen immediately after biopsy.
8. Genetic Analysis: Samples are sent to a genetics laboratory for NGS or microarray analysis; results take approximately 2–4 weeks.
9. Transfer: In the next cycle, prepare the endometrium (hormone replacement or natural cycle) and transfer a chromosomally normal blastocyst.
10. Post-Transfer Management: Luteal phase support; blood test for hCG 12–14 days after transfer to confirm pregnancy.
11. Prenatal Diagnosis: After pregnancy confirmation, chorionic villus sampling at 11–13 weeks or amniocentesis at 16–20 weeks is recommended.

N. Management of Special Situations

Mosaic Embryos

If the test result shows a low-level mosaic, the doctor will weigh the risks and opportunities of transfer based on factors such as the mosaic ratio, embryo morphology, and patient age. Detailed genetic counseling is required.

No Embryos Available for Transfer

If all embryos are aneuploid, discuss the next steps with the doctor, including: another egg retrieval cycle, using donor eggs, or accepting uncertainty.

Previous History of Down Syndrome Pregnancy

For such patients, the risk of a recurrent trisomy 21 embryo is higher than for peers of the same age. PGT-A is strongly recommended. It is also advisable for both partners to undergo chromosomal karyotyping to rule out occult translocation carriers.

Q. Frequently Asked Questions

Q1: What is the accuracy of PGT-A for screening Down syndrome in Hong Kong?

The accuracy of NGS-based PGT-A for detecting trisomy 21 is between 95% and 99%. However, it is important to understand that this is the accuracy rate for the biopsied cells and does not represent the predictive accuracy for the final chromosomal status of the fetus.

Q2: What is the approximate cost?

The cost of PGT-A in Hong Kong varies by clinic, typically including: biopsy fee (approximately HKD 15,000–25,000) + genetic analysis fee (approximately HKD 15,000–30,000 per embryo) + embryo freezing fee (approximately HKD 5,000–10,000). The total cost depends on the specific plan.

Q3: How long does it take from start to transfer?

If everything goes smoothly, from ovarian stimulation to obtaining PGT-A results and completing the transfer, it takes approximately 2–3 months (including the 2–4 weeks waiting for genetic results).

Q4: Does PGT-A damage the embryo?

Current research suggests that blastocyst biopsy performed by an experienced embryologist has a minimal impact on the embryo's continued developmental potential. However, it is not entirely risk-free; the biopsy process may cause stress or damage to the embryo, especially in less experienced laboratories.

Q5: Is amniocentesis still needed after screening?

Yes. PGT-A is a screening technology, not a diagnostic one. Amniocentesis is the gold standard for prenatal diagnosis. All patients who achieve pregnancy through PGT-A are advised to undergo confirmatory prenatal diagnosis.